StockNews.AI
NKTR
StockNews.AI
167 days

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

1. Nektar plans to announce Q4 and annual results on March 12, 2025. 2. CEO Howard Robin will host a conference call after the market closes. 3. Nektar's lead candidate, NKTR-358, is in two Phase 2b trials. 4. The company is evaluating additional potential therapies in cancer treatment. 5. Access to the call requires pre-registration via Nektar's website.

5m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results announcements typically yield uncertain market reactions, impacting stock volatility without guaranteed positive shift.

How important is it?

The announcement of financial results can set future expectations and stock performance, especially for clinical-stage companies like Nektar.

Why Short Term?

The upcoming earnings report is a near-term catalyst that could affect stock movements temporarily.

Related Companies

IMMUBCRXCRBP
, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 12, 2025. To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow Nektar on LinkedIn. Contacts: For Investors:Vivian Wu of Nektar Therapeutics(628) 895-0661 For Media:Madelin HawtinLifeSci Communications603-714-2638[email protected] SOURCE Nektar Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News